Peer-reviewed veterinary case report
Longer survival linked to TP53 mutations in dog bone cancer
By Das, Sunetra et al.·Published in Communications biology·2021·Department of Clinical Sciences, United States·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Immune pathways and TP53 missense mutations are associated with longer survival in canine osteosarcoma.
- Species:
- dog
Plain-English summary
A study found that dogs with osteosarcoma (a type of bone cancer) who had specific mutations in a gene called TP53 and lower levels of certain white blood cells in their blood tended to live longer after treatment. The research looked at various genetic changes in cancer samples from dogs and found that those with the TP53 mutation had better disease-free intervals, meaning they went longer without the cancer returning. This information could help veterinarians develop better treatment plans for dogs with osteosarcoma.
People also search for: dog osteosarcoma survival rate · TP53 mutation in dogs · treatment options for dog bone cancer
Abstract
Osteosarcoma affects about 2.8% of dogs with cancer, with a one-year survival rate of approximately 45%. The purpose of this study was to characterize mutation and expression profiles of osteosarcoma and its association with outcome in dogs. The number of somatic variants identified across 26 samples ranged from 145 to 2,697 with top recurrent mutations observed in TP53 and SETD2. Additionally, 47 cancer genes were identified with copy number variations. Missense TP53 mutation status and low pre-treatment blood monocyte counts were associated with a longer disease-free interval (DFI). Patients with longer DFI also showed increased transcript levels of anti-tumor immune response genes. Although, T-cell and myeloid cell quantifications were not significantly associated with outcome; immune related genes, PDL-1 and CD160, were correlated with T-cell abundance. Overall, the association of gene expression and mutation profiles to outcome provides insights into pathogenesis and therapeutic interventions in osteosarcoma patients.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/34635775/